MEI Pharma (MEIP) Issues Letter to Shareholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St futures rise on Mideast deal optimism; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
June 29, 2023 8:00 AM EDTHighlights Shareholder Opportunity to Participate in Upside Potential of Diversified Combined Pipeline of Three Clinical-Stage Development Programs
Combined Company Well-Positioned to Make a Difference in Cancer Care With Significant Potential to Deliver Improved Therapeutic Options for Patients
Board Reiterates Recommendation to Shareholders to Vote FOR the Merger Agreement with Infinity Pharmaceuticals Ahead of the Special Meeting of MEI Pharma Shareholders on July 14, 2023
SAN DIEGO--(BUSINESS WIRE)-- MEI Pharma, Inc. (NASDAQ: MEIP) (the Company) today issued the following letter to shareholders reiterating the Board of... More
